XCSFDHG46767FHJHJF
tdp2664 China Analyst Below are the top 10 Biotech stocks with highest upside potential, based on the difference between current price and Wall Street analysts' average target price. One Chinese company (CPHI) is on the list. Bionovo Inc. (NASDAQ:BNVI) has the 1st highest upside potential in this segment of the market. Its upside is 825.8%. Its consensus target price is $5.00 based on the average of all estimates. Palatin Technologies, Inc. (AMEX:PTN) has the 2nd highest upside potential in this segment of the market. Its upside is 694.9%. Its consensus target price is $5.00 based on the average of all estimates. Peregrine Pharmaceuticals (NASDAQ:PPHM) has the 3rd highest upside potential in this segment of the market. Its upside is 612.5%. Its consensus target price is $7.13 based on the average of all estimates. Galena Biopharma Inc (NASDAQ:GALE) has the 4th highest upside potential in this segment of the market. Its upside is 517.3%. Its consensus target price is $4.50 based on the average of all estimates. Neostem Inc. (AMEX:NBS) has the 5th highest upside potential in this segment of the market. Its upside is 473.7%. Its consensus target price is $3.56 based on the average of all estimates. CEL-SCI Corporation (AMEX:CVM) has the 6th highest upside potential in this segment of the market. Its upside is 455.6%. Its consensus target price is $2.00 based on the average of all estimates. Tengion, Inc. (NASDAQ:TNGN) has the 7th highest upside potential in this segment of the market. Its upside is 440.8%. Its consensus target price is $2.65 based on the average of all estimates. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has the 8th highest upside potential in this segment of the market. Its upside is 415.3%. Its consensus target price is $6.75 based on the average of all estimates. China Pharma Holdings, Inc. (AMEX:CPHI) has the 9th highest upside potential in this segment of the market. Its upside is 405.6%. Its consensus target price is $4.50 based on the average of all estimates. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has the 10th highest upside potential in this segment of the market. Its upside is 374.7%. Its consensus target price is $7.50 based on the average of all estimates.
No comments:
Post a Comment